Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Pulmonx (LUNG) Shares Issued (2019 - 2025)

Pulmonx has reported Shares Issued over the past 7 years, most recently at $5000.0 for Q3 2025.

Quarterly Shares Issued fell 82.14% to $5000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $253000.0 through Sep 2025, up 47.09% year-over-year, with the annual reading at $218000.0 for FY2024, 29.68% down from the prior year.
Shares Issued was $5000.0 for Q3 2025 at Pulmonx, down from $28000.0 in the prior quarter.
Over five years, Shares Issued peaked at $1.3 million in Q2 2021 and troughed at $5000.0 in Q3 2025.
The 5-year median for Shares Issued is $72000.0 (2022), against an average of $167684.2.
Year-over-year, Shares Issued surged 982.35% in 2021 and then crashed 86.66% in 2022.
A 5-year view of Shares Issued shows it stood at $150000.0 in 2021, then grew by 26.67% to $190000.0 in 2022, then crashed by 66.32% to $64000.0 in 2023, then soared by 71.88% to $110000.0 in 2024, then tumbled by 95.45% to $5000.0 in 2025.
Per Business Quant, the three most recent readings for LUNG's Shares Issued are $5000.0 (Q3 2025), $28000.0 (Q2 2025), and $110000.0 (Q1 2025).